Denosumab for the treatment of adult multisystem Langerhans cell histiocytosis
- 1 April 2017
- journal article
- Published by Elsevier BV in Metabolism
- Vol. 69, 107-111
- https://doi.org/10.1016/j.metabol.2017.01.004
Abstract
No abstract availableKeywords
This publication has 12 references indexed in Scilit:
- Clinical Characteristics and Treatment of Langerhans Cell HistiocytosisHematology/Oncology Clinics of North America, 2015
- Novel therapies for osteoporosisMetabolism, 2015
- Rationale for the Application of RANKL Inhibition in the Treatment of Langerhans Cell HistiocytosisJournal of Clinical Endocrinology & Metabolism, 2015
- Pathogenesis of Langerhans Cell HistiocytosisAnnual review of pathology, 2013
- Management of adult patients with Langerhans cell histiocytosis: recommendations from an expert panel on behalf of Euro-Histio-NetOrphanet Journal of Rare Diseases, 2013
- Denosumab Dose Selection for Patients with Bone Metastases from Solid TumorsClinical Cancer Research, 2012
- Serum Osteoprotegerin, RANKL, and Dkk-1 Levels in Adults with Langerhans Cell HistiocytosisJournal of Clinical Endocrinology & Metabolism, 2012
- Population Pharmacokinetic Analysis of Denosumab in Patients with Bone Metastases from Solid TumoursClinical Pharmacokinetics, 2012
- Endocrine manifestations in Langerhans cell histiocytosisTrends in Endocrinology & Metabolism, 2007
- Adult pulmonary Langerhans' cell histiocytosisEuropean Respiratory Journal, 2006